[1] Cowden Dahl K, Bobbs A, Cole J, et al. Emerging and evolving ovarian cancer animal models[J]. Cancer Growth Metast, 2015, 8(Suppl 1):29-36.
[2] Shireen R, Brennan D, Flannelly G, et al. Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review[J]. Ir Med J, 2012, 105(2):47-50.
[3] 王淳, 李士怡, 王晓波, 等.消癌平注射液抑制卵巢癌细胞(Caov-3)侵袭的作用及可能机制[J].解剖科学进展, 2011, 17(2):144-146.
[4] 李凤霞, 宋爱英, 唐寅, 等.消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌的临床观察[J].中国药房, 2015, 26(20):2815-2817.
[5] Harris JW, Rahman A, Kim BR, et al. Metabolism of taxol by human hepatic microsomes and liver slices:participation of cytochrome P4503A4 and an unknown P450 enzyme[J]. Cancer Res, 1994, 54(15):4026-4035.
[6] Backman JT, Filppula AM, Niemi M, et al.Role of Cytochrome P4502C8 in drug metabolism and interactions[J]. Pharmacol Rev, 2016, 68(1):168-241.
[7] Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine[J]. Proc Natl Acad Sci USA, 1997, 94(5):2031-2035.
[8] Crommentuyn KM, Schellens JH, van den Berg JD, et al. In-vitro metabolism of anti-cancer drugs, methods and applications:paclitaxel, docetaxel, tamoxifen and ifosfamide[J]. Cancer Treat Rev, 1998, 24(5):345-366.
[9] 刘丽雅, 韩永龙, 余奇, 等. 消癌平注射液等4种抗肿瘤中药注射剂对人肝微粒体中CYP450酶7种亚型的体外抑制作用研究[J]. 中国临床药理学与治疗学, 2014, 19(5):522-527.
[10] 谢丽艳. 消癌平注射液药物相互作用研究[D]. 南京:南京中医药大学, 2013.
[11] 曾庆花. 消癌平注射液的药代动力学及相互作用研究[D]. 上海:第二军医大学, 2013.